MindMed Archives

Psychedelics News

MindMed

Science

14 Dec 2023

MindMed Announces Positive Results from Phase 2b Anxiety Trial

Big news as the trial met its primary endpoint, with 50% clinical remission rate at Week 4....

By Microdose NewsDesk

Industry

12 Sep 2023

MindMed Completes Dosing of Phase 2b Trial

MindMed has completed dosing of its main Phase 2b clinical trial. The study — investigating LSD for Generalized Anxiety Disorder (GAD) — has dosed 198 participants across 20 clinical sites....

By Microdose NewsDesk

Finance

15 Aug 2023

MindMed Secures $50 Million Loan From K2 HealthVentures

MindMed secures $50 Million credit facility with K2 HealthVentures, giving company access to additional capital...

By Microdose NewsDesk

Finance

4 Aug 2023

MindMed Reports Second Quarter 2023 Financial Results and Highlights

MindMed released its Q3 financial results. Highlights include enrolment in Phase 2b LSD trial, top-line results by end-of-year, and $116 million in cash....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

6 Jun 2023

Candyflipping: New MindMed-Owned Study Looks at Combining MDMA and LSD

The new study, published this week in Nature, investigated whether MDMA can be used to optimize some of the effects of LSD, by adding some of the more positive mood...

By Jason Najum

Breaking News

25 May 2023

MindMed Publishes Report by FDA Experts: Is FCM’s Takeover Attempt Over?

A group of activist investors are trying to take control of MindMed’s board of directors. Today, MindMed has pushed back, potentially dealing a final blow to this increasingly suspect attempted...

By Jason Najum

Don’t Miss

22 May 2023

News You Might Have Missed: May 22nd 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

18 May 2023

MindMed Announces Milestone in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

MindMed announced that the company’s Phase 2b study evaluating MM-120 (lysergide D-tartrate) for GAD is over 50% enrolled and dosed....

By Microdose NewsDesk

Finance

8 May 2023

Which Psychedelic Medicine Companies Have the Best Financials?

As I have written many times before, the success or failure of a psychedelic medicine company depends heavily on its financial position....

By James Hallifax

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result